October 31, 2022
Novartis has filed an appeal against a US district court ruling last month that its cancer drug Tafinlar (dabrafenib) infringes two US patents owned by Daiichi Sankyo’s now-defunct Plexxikon unit, the Japanese company said on October 28. In August 2017,...read more